{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:50:44Z","timestamp":1789941044093,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ijcard.2012.08.014","type":"journal-article","created":{"date-parts":[[2012,9,16]],"date-time":"2012-09-16T13:01:24Z","timestamp":1347800484000},"page":"2449-2455","source":"Crossref","is-referenced-by-count":27,"title":["Novel oral anticoagulants in acute coronary syndrome"],"prefix":"10.1016","volume":"167","author":[{"given":"Charis","family":"Costopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Niespialowska-Steuden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neville","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana A.","family":"Gorog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2012.08.014_bb0005","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.jacc.2011.08.042","article-title":"The year in non-ST-segment elevation acute coronary syndrome","volume":"58","author":"Giugliano","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0010","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/01.CIR.90.2.775","article-title":"Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture","volume":"90","author":"Moreno","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis-an inflammatory disease","volume":"34","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0020","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/35025229","article-title":"Thrombin signalling and protease-activated receptors","volume":"407","author":"Coughlin","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.blre.2008.06.002","article-title":"Protease-activated receptors as targets for antiplatelet therapy","volume":"23","author":"Hamilton","year":"2009","journal-title":"Blood Rev"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0030","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ncpcardio1302","article-title":"Time course of events in acute coronary syndromes: Implications for clinical practice from the GRACE registry","volume":"5","author":"Fox","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0035","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0040","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0260","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(96)91270-2","article-title":"Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during instability in coronary artery disease (FRISC) study group","volume":"347","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0050","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0055","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data","volume":"374","author":"S\u00f8rensen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0060","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJM199106273242606","article-title":"Oral anticoagulant drugs","volume":"324","author":"Hirsh","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0065","doi-asserted-by":"crossref","first-page":"204S","DOI":"10.1378\/chest.126.3_suppl.204S","article-title":"The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy","volume":"126","author":"Ansell","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0070","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0080","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"NEJM"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0270","series-title":"Presented at XXII Congress of the International Society on Thrombosis and Hemostasis","article-title":"LB-MO-005 Late breaking clinical trial: The ADVANCE\u20142 study: A randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement","author":"Lassen","year":"2009"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0090","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0095","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0275","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"NEJM"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0110","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0285","first-page":"226","article-title":"'Rivaroxaban: A Direct Factor Xa Inhibitor for VTE Prophylaxis in Patients Undergoing Total Knee or Hip Replacement Surgery.'","volume":"44","author":"Wong","year":"2009","journal-title":"Formulary"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0120","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"NEJM"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (Atlas Acs-Timi 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0290","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"ATLAS ACS 2\u2010TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"NEJM"},{"issue":"Suppl. 2","key":"10.1016\/j.ijcard.2012.08.014_bb0295","first-page":"360","article-title":"Co-administration of darexaban (YM150), an oral direct factor Xa inhibitor, with acetylsalicylic acid, clopidogrel and naproxen: no evidence of clinically relevant interactions","volume":"9","author":"Heeringa","year":"2007","journal-title":"J Thromb Hemost"},{"issue":"Suppl. 2","key":"10.1016\/j.ijcard.2012.08.014_bb0140","first-page":"359","article-title":"The pharmacokinetics of YM150, an oral direct factor Xa inhibitor, are not affected to a clinically relevant degree by strong inhibition or induction of CYP3A4 and P-gp","volume":"9","author":"Heeringa","year":"2011","journal-title":"J Thromb Hemost"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0145","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1538-7836.2010.03748.x","article-title":"ONYX-2 STUDY GROUP. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)","volume":"8","author":"Eriksson","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0300","unstructured":"Astellas Pharma Europe BV. A study evaluating safety and tolerability of YM150 compared to warfarin in subjects with atrial fibrillation (OPAL-2). Astellas Pharma Inc. Clinicaltrials.gov identifier: NCT00938730. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00938730?term=NCT00938730&rank=1."},{"key":"10.1016\/j.ijcard.2012.08.014_bb0155","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehr334","article-title":"RUBY-1 Investigators. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome","volume":"32","author":"Steg","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0160","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0305","author":"Pradaxa"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0170","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/j.jacc.2010.09.017","article-title":"Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments","volume":"56","author":"Schirmer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0175","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"NEMJ"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0180","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the Re-Ly trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0185","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0190","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/eurheartj\/ehl564","article-title":"Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial","volume":"28","author":"Christersson","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0195","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1476-5381.2009.00555.x","article-title":"Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases","volume":"15","author":"Siller-Matula","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0200","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(09)60230-0","article-title":"TRA-PCI Investigators. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study","volume":"373","author":"Becker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0205","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5551\/jat.3038","article-title":"Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome","volume":"17","author":"Goto","year":"2010","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0210","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"NEMJ"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0215","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1161\/CIRCULATIONAHA.110.000786","article-title":"LANCELOT-ACS Investigators. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin\u2013Acute Coronary Syndromes Trial","volume":"123","author":"O'Donoghue","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0220","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/eurheartj\/ehq320","volume":"31","author":"Goto","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0225","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0230","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0235","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/FTD.0b013e3181f2f264","article-title":"Assays for measuring rivaroxaban: their suitability and limitations","volume":"32","author":"Lindhoff-Last","year":"2010","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0240","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1160\/TH10-05-0328","article-title":"Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay","volume":"104","author":"Barrett","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0245","doi-asserted-by":"crossref","first-page":"119S","DOI":"10.1177\/0091270011415527","article-title":"Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment","volume":"52","author":"Hariharan","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0250","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"NEMJ"},{"key":"10.1016\/j.ijcard.2012.08.014_bb0255","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"NEMJ"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527312010285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527312010285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T20:12:04Z","timestamp":1562184724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527312010285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0167527312010285"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2012.08.014","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}